title: Polymer-based, paclitaxel-eluting TAXUS Liberté stent in de novo lesions: the pivotal TAXUS ATLAS trial.
abstract: OBJECTIVE
  The goal of this research was to assess non-inferiority of the next-generation TAXUS Liberté stent (Boston Scientific Corp., Natick, Massachusetts) versus the TAXUS Express stent (Boston Scientific Corp.).
  
  
  BACKGROUND
  The introduction of drug-eluting stents (DES) has shifted clinical practice towards more complex lesion subsets, prompting the need for more deliverable DES. TAXUS Liberté was designed to combine the established polymer-based, paclitaxel-elution TAXUS technology with the more advanced Liberté stent platform.
  
  
  METHODS
  The TAXUS ATLAS study is a global, prospective, single-arm trial evaluating outcomes in de novo coronary lesions visually estimated to be 10 to 28 mm in length in vessels 2.5 to 4.0 mm in diameter. The control group is an entry-criteria-matched population of TAXUS Express patients from the TAXUS IV and V trials. The primary end point is non-inferiority of TAXUS Liberté versus TAXUS Express for 9-month target vessel revascularization.
  
  
  RESULTS
  Despite similar inclusion criteria, quantitative coronary angiography-determined baseline lesion characteristics were significantly more complex for TAXUS Liberté than TAXUS Express. The primary non-inferiority end point was met with the 1-sided 95% confidence bound of 2.98% less than the pre-specified non-inferiority margin of 3% (p = 0.0487).
  
  
  CONCLUSIONS
  Despite the treatment of more complex lesions with TAXUS Liberté, the primary end point was met, demonstrating that TAXUS Liberté is non-inferior to TAXUS Express. The successful transfer of the proven TAXUS technology to the more advanced TAXUS Liberté platform was demonstrated. (TAXUS ATLAS: TAXUS Liberté-SR Stent for the Treatment of De Novo Coronary Artery Lesions; http://www.clinicaltrials.gov/ct/show/NCT00371709?order=1; NCT00371709).
authors: Center for Cardiac & Vascular Research, Washington Adventist Hospital, Takoma Park, Maryland 20912, USA. MTurco@ahm.com
authors: Mark A
authors: MA
authors: Turco
authors: John A
authors: JA
authors: Ormiston
authors: Jeffrey J
authors: JJ
authors: Popma
authors: Lazar
authors: L
authors: Mandinov
authors: Charles D
authors: CD
authors: O'Shaughnessy
authors: Tift
authors: T
authors: Mann
authors: Thomas F
authors: TF
authors: McGarry
authors: Chiung-Jen
authors: CJ
authors: Wu
authors: Charles
authors: C
authors: Chan
authors: Mark W I
authors: MW
authors: Webster
authors: Jack J
authors: JJ
authors: Hall
authors: Gregory J
authors: GJ
authors: Mishkel
authors: Louis A
authors: LA
authors: Cannon
authors: Donald S
authors: DS
authors: Baim
authors: Joerg
authors: J
authors: Koglin
mesh_terms: D000368:Aged; D023921:Coronary Stenosis / Q000188:drug therapy*; D023381:Endpoint Determination; D004867:Equipment Design; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D017239:Paclitaxel / Q000008:administration & dosage*; D011108:Polymers; D011446:Prospective Studies; D015607:Stents; D050257:Tubulin Modulators / Q000008:administration & dosage*
chemical_list: D011108:Polymers; D050257:Tubulin Modulators; D017239:Paclitaxel